The Sleeping Giant
August 13, 2019
-
3 min
The pharmaceutical industry faces a significant challenge regarding antibiotic development due to a lack of profit, leading to stagnation in innovation. Despite the potential found in natural sources like fish slime and fungus, and various government funding initiatives, there has been little progress. A new subscription payment model announced in the UK aims to encourage antibiotic development by compensating companies irrespective of sales volume. This innovative approach may inspire similar initiatives worldwide, highlighting the need for pharma to rethink funding strategies for essential drug development.
1. Antibiotic development is hindered by a lack of profit. 2. Innovative natural sources may provide new antibiotics. 3. Government initiatives are crucial for funding. 4. UK introduces a subscription payment model. 5. The model compensates for unused antibiotics. 6. Pharma must be proactive in funding R&D. 7. There's a call for reassessment in antibiotic strategy.
Listen Tab content
